<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00221754</url>
  </required_header>
  <id_info>
    <org_study_id>9268-02</org_study_id>
    <secondary_id>2001-026</secondary_id>
    <nct_id>NCT00221754</nct_id>
  </id_info>
  <brief_title>Pravastatin and Protease Inhibitors in HIV-Infected Patients</brief_title>
  <official_title>Pravastatin in HIV-Infected Patients Treated With Highly Active Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the use of pravastatin in hypercholesterolemic HIV-infected patients treated with
      protease inhibitors in a randomised double blind study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background. Highly Active AntiRetroviral Therapy including protease inhibitors is associated
      with elevated plasma lipid levels.

      Design. randomized double-blind, multicentric.

      Intervention. Pravastatin versus placebo for 12 weeks.

      Eligibility criteria. Positive for anti-VIH antibodies, stable antiretroviral therapy
      including at least one PI for &gt;= 3 months, plasma HIV-RNA level of &lt; 50 copies/mL for &gt;= 3
      months before randomization, total cholesterol &gt;= 5.5 mmol/L with LDL-cholesterol &gt;= 3.4
      mmol/L on fasting status after three months of standardized dietary advice, written informed
      consent

      Outcomes. HIV RNA at 12 weeks
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">March 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV RNA</measure>
    <time_frame>at 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid biological markers</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of protease inhibitors</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 count at 12 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <enrollment type="Actual">21</enrollment>
  <condition>HIV Infection</condition>
  <condition>Hypercholesterolemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin (drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed HIV-1 infection (ELISA confirmed by Western-Blot test) ;

          -  Age above 18 years

          -  Stable antiretroviral therapy including at least one PI for &gt;= 3 months,

          -  Plasma HIV-RNA level of &lt; 50 copies/mL for &gt;= 3 months before randomization,

          -  Total cholesterol &gt; = 5.5 mmol/L with LDL-cholesterol &gt; = 3.4 mmol/L on fasting status
             after three months of standardized dietary advice,

          -  signed informed consent

        Exclusion Criteria:

          -  Current AIDS event or infectious disease

          -  Tumoral, inflammatory, muscle diseases; kidney or hepatic failure

          -  Psychiatric conditions

          -  Biological elevated muscular enzymes

          -  Chronic alcohol consumption

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice BONNET, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bordeaux, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geneviève CHENE, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Saint André, Service de médecine interne et maladies infectieuses</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>June 12, 2007</last_update_submitted>
  <last_update_submitted_qc>June 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2007</last_update_posted>
  <keyword>HIV,</keyword>
  <keyword>protease inhibitors</keyword>
  <keyword>pravastatin</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

